Paroxetine Mesylate

CHEMBL1200609 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

425.5 g/mol

LogP

—

Phase

4

A mesylate salt form of paroxetine with the same therapeutic properties. This SSRI antidepressant treats depression, anxiety disorders, obsessive-compulsive disorder, and other mental health conditions.

Moleküler Ağırlık

425,5000 g/mol

TPSA

102,00 Å²

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Hepatitis C Prostate Cancer Colorectal Cancer

Etki Mekanizması

Potent selective serotonin reuptake inhibitor with additional muscarinic and NE reuptake inhibition.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Potent selective serotonin reuptake inhibitor with additional muscarinic and NE reuptake inhibition.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CS(=O)(=O)O.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1

InChI

InChI=1S/C19H20FNO3.CH4O3S/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;1-5(2,3)4/h1-6,9,14,17,21H,7-8,10-12H2;1H3,(H,2,3,4)/t14-,17-;/m0./s1

Molecular Formula

C20H24FNO6S

HBD / HBA

2 / 8

Döndürülebilir Bağlar

4

Ağır Atomlar

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A mesylate salt form of paroxetine with the same therapeutic properties. This SSRI antidepressant treats depression, anxiety disorders, obsessive-compulsive disorder, and other mental health conditions.

Potent selective serotonin reuptake inhibitor with additional muscarinic and NE reuptake inhibition.

Yes, Paroxetine Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200609. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9845306. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Paroxetine Mesylate PillFYI'da

Yapı

Hızlı Veriler

Formül: C20H24FNO6S

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Paroxetine Mesylate

Terapötik Alanlar

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget